AbbVie Inc. (NYSE:ABBV) Shares Sold by Moody National Bank Trust Division

Moody National Bank Trust Division lessened its stake in AbbVie Inc. (NYSE:ABBV) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,517 shares of the company’s stock after selling 951 shares during the quarter. Moody National Bank Trust Division’s holdings in AbbVie were worth $4,001,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Wedmont Private Capital grew its holdings in AbbVie by 16.5% in the 4th quarter. Wedmont Private Capital now owns 25,822 shares of the company’s stock worth $4,523,000 after buying an additional 3,654 shares in the last quarter. Talbot Financial LLC raised its holdings in shares of AbbVie by 4.9% in the 4th quarter. Talbot Financial LLC now owns 96,509 shares of the company’s stock worth $17,150,000 after purchasing an additional 4,503 shares in the last quarter. Salem Investment Counselors Inc. boosted its stake in shares of AbbVie by 0.9% during the 4th quarter. Salem Investment Counselors Inc. now owns 132,253 shares of the company’s stock worth $23,501,000 after acquiring an additional 1,231 shares in the last quarter. Fragasso Financial Advisors Inc raised its holdings in AbbVie by 1.4% during the 4th quarter. Fragasso Financial Advisors Inc now owns 12,772 shares of the company’s stock worth $2,270,000 after buying an additional 180 shares during the period. Finally, Agate Pass Investment Management LLC raised its holdings in shares of AbbVie by 8.9% during the fourth quarter. Agate Pass Investment Management LLC now owns 64,956 shares of the company’s stock valued at $11,543,000 after acquiring an additional 5,314 shares during the period. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on ABBV. Barclays increased their target price on shares of AbbVie from $200.00 to $212.00 and gave the stock an “overweight” rating in a research report on Monday, October 7th. Daiwa America lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 5th. Piper Sandler raised their target price on shares of AbbVie from $212.00 to $220.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Daiwa Capital Markets downgraded shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 price target for the company. in a report on Thursday, December 5th. Finally, Leerink Partnrs raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $205.50.

AbbVie Trading Up 1.3 %

ABBV stock traded up $2.25 during trading on Monday, hitting $177.42. The company had a trading volume of 2,026,118 shares, compared to its average volume of 4,639,041. The stock has a market cap of $313.53 billion, a price-to-earnings ratio of 61.60, a PEG ratio of 1.92 and a beta of 0.58. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The firm has a 50-day moving average price of $178.47 and a 200-day moving average price of $184.55. AbbVie Inc. has a 12 month low of $153.58 and a 12 month high of $207.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.92 by $0.08. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The firm had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.28 billion. During the same quarter last year, the business earned $2.95 earnings per share. The company’s revenue was up 3.8% compared to the same quarter last year. As a group, analysts predict that AbbVie Inc. will post 10.96 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 3.70%. This is a boost from AbbVie’s previous quarterly dividend of $1.55. The ex-dividend date of this dividend is Wednesday, January 15th. AbbVie’s payout ratio is presently 227.78%.

Insider Transactions at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now owns 6,983 shares of the company’s stock, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.25% of the stock is currently owned by insiders.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.